Hard knocks for brain cancer, again
In the wake of two phase III glioblastoma failures this month, from Abbvie and Bristol-Myers Squibb, hopes dim for another big readout from Tocagen.
Upcoming events – crucial cancer data for Tocagen and Syndax
Tocagen could soar or sink on interim brain cancer data, while judgement day approaches for Syndax.
Upcoming events – Tocagen’s brain cancer data and Restorbio tackles respiratory infections
Mid-stage data for Tocagen and Restorbio are approaching.
Biotech floats come back with a vengeance
The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.
